HR-pQCT Detects Alterations in Bone Microstructure in Men with CKD Stages 3 and 4, Which Are Influenced by Hormonal Changes and Body Composition
Overview
Authors
Affiliations
Introduction: Factors associated with osteodystrophy in predialysis patients are poorly understood. In the present study, we attempted to evaluate the impact of body composition and hormonal regulatory factors on the bone microstructure in a group of men with chronic kidney disease (CKD) stages 3 and 4.
Materials And Methods: 46 men, aged 50 - 75 years, with previously unrecognized CKD were evaluated by high-resolution peripheral quantitative computed tomography (HR-pQCT), and dual-energy X-ray absorptiometry (DXA). HR-pQCT parameters were correlated with estimated glomerular filtration rate (eGFR), age, body mass index (BMI), muscle mass index (MMI), and biochemistry.
Results: As compared to patients in stage 3 CKD, those with stage 4 CKD showed lower serum 25-hydroxyvitamin D (25(OH)D) and bicarbonate levels, and higher serum fibroblast growth factor 23 (FGF-23) and parathyroid hormone (PTH) levels. They also exhibited lower total, trabecular, and cortical volumetric bone mineral density, lower trabecular bone volume/tissue volume, trabecular number, trabecular and cortical thickness, and increased heterogeneity of the trabecular network. In the whole cohort, cortical bone density and thickness were negatively associated with age, PTH, and FGF-23, and positively with BMI. Trabecular bone parameters were positively associated with MMI and 25(OH)D. After simultaneously adjusting for age and eGFR, BMI, and MMI remained significantly associated with bone microstructural variables.
Conclusion: HR-pQCT showed significant differences in bone microstructure in stage 4 vs. stage 3 CKD patients. Increased BMI, probably due to increased muscle mass, may favorably affect bone architecture in predialysis CKD patients. .
Fusaro M, Pereira L, Bover J J Clin Med. 2023; 12(19).
PMID: 37834950 PMC: 10573159. DOI: 10.3390/jcm12196306.
Tsuji K, Kitamura M, Chiba K, Muta K, Yokota K, Okazaki N Ren Fail. 2022; 44(1):381-391.
PMID: 35220856 PMC: 8890516. DOI: 10.1080/0886022X.2022.2043375.
van den Bergh J, Szulc P, Cheung A, Bouxsein M, Engelke K, Chapurlat R Osteoporos Int. 2021; 32(8):1465-1485.
PMID: 34023944 PMC: 8376700. DOI: 10.1007/s00198-021-05999-z.
The Non-invasive Diagnosis of Bone Disorders in CKD.
Bover J, Urena-Torres P, Cozzolino M, Rodriguez-Garcia M, Gomez-Alonso C Calcif Tissue Int. 2021; 108(4):512-527.
PMID: 33398414 DOI: 10.1007/s00223-020-00781-5.
TGF-Beta Signaling in Bone with Chronic Kidney Disease.
Iwasaki Y, Yamato H, Fukagawa M Int J Mol Sci. 2018; 19(8).
PMID: 30103389 PMC: 6121599. DOI: 10.3390/ijms19082352.